Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.61 |
| ▸ | CTSL | P07711 | 3/20 | 0.61 |
| ▸ | CTSS | P25774 | 3/20 | 0.61 |
| ▸ | PPARA | Q07869 | 5/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | KYNU | Q16719 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410812 | 1.00 | CTSK (0.61) | CTSKCTSLCTSSPPARACTSB | |
| SCHEMBL1409909 | 1.00 | CTSK (0.61) | CTSKCTSLCTSSPPARACTSB | |
| SCHEMBL3821264 | 0.95 | CTSK (0.62) | CTSKCTSLCTSSPPARACTSB | |
| SCHEMBL31276612 | 0.95 | CTSK (0.62) | CTSKCTSLCTSSPPARACTSB | |
| SCHEMBL3824387 | 0.91 | CTSL (0.64) | CTSKCTSLCTSSPPARACTSB | |
| SCHEMBL1409906 | 0.91 | CTSK (0.60) | CTSKCTSLCTSSPPARACTSB | |
| SCHEMBL29401640 | 0.91 | CTSK (0.63) | CTSKCTSLCTSSCTSBSYK | |
| SCHEMBL344382 | 0.91 | CTSK (0.63) | CTSKCTSLCTSSCTSBSYK | |
| SCHEMBL344381 | 0.91 | CTSK (0.63) | CTSKCTSLCTSSCTSBSYK | |
| SCHEMBL30999365 | 0.90 | CTSK (0.58) | CTSKCTSLCTSSPPARACTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | claimed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | claimed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | claimed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-109928971-B | Aryl substituted aminotetrahydropyrans and uses thereof | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-9242926-B2 | Processes for the preparation of lacosamide and intermediates thereof | CADILA HEALTHCARE LIMITED (IN) | 2016-01-26 | — | — | US | disclosed |
| US-8940722-B2 | Compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2015-01-27 | — | — | US | disclosed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | disclosed |
| WO-2007050612-A1 | 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | BAYER HEALTHCARE AG (DE) | 2005-04-07 | — | — | US | disclosed |
| US-20030092067-A1 | Substrates and inhibitors of proteolytic enzymes | PEPTIDE THERAPEUTICS LIMITED | 2003-05-15 | — | — | US | disclosed |
| US-6528275-B1 | Screening for cleavage using combinatorial fluorescence resonance energy transfer (FRET) compounds of given formula; can use to accelerate drug discovery process | PEPTIDE THERAPEUTICS LIMITED (GB) | 2003-03-04 | — | — | US | disclosed |
| EP-0906333-B1 | SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES | MEDIVIR UK LTD (GB) | 2001-07-25 | — | — | EP | disclosed |
| EP-0906333-A2 | SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997040065-A2 | SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | VIP, LNPEP, HAMP | CTSK 393/4885CTSL 65/4885CTSS 459/4885 |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | ACKR3, KIT, C3AR1 | CTSK 1088/4885CTSL 1121/4885CTSS 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.